Published in J Clin Microbiol on August 01, 2000
Highly sensitive multiplex assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA. J Clin Microbiol (2002) 1.46
Comparison of two human immunodeficiency virus (HIV) RNA surrogate assays to the standard HIV RNA assay. J Clin Microbiol (2005) 1.27
Real-time PCR quantification of genital shedding of herpes simplex virus (HSV) and human immunodeficiency virus (HIV) in women coinfected with HSV and HIV. J Clin Microbiol (2006) 1.26
HIV dynamics in seminal plasma during primary HIV infection. AIDS Res Hum Retroviruses (2008) 1.14
Strengths and limitations of commercial tests for hepatitis C virus RNA quantification. J Clin Microbiol (2004) 1.12
Comparison of the LCx human immunodeficiency virus (HIV) RNA quantitative, RealTime HIV, and COBAS AmpliPrep-COBAS TaqMan assays for quantitation of HIV type 1 RNA in plasma. J Clin Microbiol (2006) 0.98
Evaluation of the clinical sensitivities of three viral load assays with plasma samples from a pediatric population predominantly infected with human immunodeficiency virus type 1 subtype G and BG recombinant forms. J Clin Microbiol (2003) 0.95
Multicenter evaluation of the performance characteristics of the NucliSens HIV-1 QT assay used for quantitation of human immunodeficiency virus type 1 RNA. J Clin Microbiol (2003) 0.85
Intra- and interlaboratory variabilities of results obtained with the Quantiplex human immunodeficiency virus type 1 RNA bDNA assay, version 3.0. Clin Diagn Lab Immunol (2001) 0.84
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 21.81
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science (1996) 18.38
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med (1997) 16.44
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med (1999) 7.07
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med (1999) 5.18
Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA (1999) 4.98
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet (1999) 4.83
Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories. J Clin Microbiol (1996) 4.81
A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml. Nucleic Acids Res (1997) 4.40
Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med (1997) 3.71
Misdiagnosis of HIV infection by HIV-1 plasma viral load testing: a case series. Ann Intern Med (1999) 3.37
Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 3.23
Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (1998) 2.94
Quantification of HIV-1 RNA in plasma using NASBA during HIV-1 primary infection. J Virol Methods (1993) 2.24
Clinical and immunologic response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy. Clin Infect Dis (1999) 2.17
Evaluation of the ultrasensitive Roche Amplicor HIV-1 monitor assay for quantitation of human immunodeficiency virus type 1 RNA. J Clin Microbiol (1999) 1.92
Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS (1998) 1.81
A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: enhanced sensitivity. J Clin Microbiol (1997) 1.68
CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet (1998) 1.62
Comparison of the Quantiplex version 3.0 assay and a sensitized Amplicor monitor assay for measurement of human immunodeficiency virus type 1 RNA levels in plasma samples. J Clin Microbiol (1999) 1.25
The effects of zidovudine in the subset of infants infected with human immunodeficiency virus type-1 (Pediatric AIDS Clinical Trials Group Protocol 076). J Pediatr (1999) 0.94
Viral RNA in the resolution of human immunodeficiency virus type 1 diagnostic serology. Transfusion (1997) 0.83
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet (1999) 18.20
Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med (2010) 12.08
Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med (1998) 6.88
Biological and virologic characteristics of primary HIV infection. Ann Intern Med (1998) 5.45
Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet (1991) 5.42
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS (2001) 5.31
Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories. J Clin Microbiol (1996) 4.81
Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS (2001) 4.76
Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Lancet (1999) 4.61
Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med (1996) 4.44
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med (1996) 4.43
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med (1996) 4.03
Carnitine--metabolism and functions. Physiol Rev (1983) 3.57
Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med (1987) 3.42
Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (1998) 2.94
Do corals lie about their age? Some demographic consequences of partial mortality, fission, and fusion. Science (1980) 2.84
Hurricane Allen's Impact on Jamaican Coral Reefs. Science (1981) 2.76
Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest (1996) 2.65
The effect of fasting on the activity of liver carnitine palmitoyltransferase and its inhibition by malonyl-CoA. Biochim Biophys Acta (1981) 2.62
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med (1997) 2.55
A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med (1990) 2.48
Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol (1996) 2.47
A whole blood immunoassay using gold nanoshells. Anal Chem (2003) 2.45
Predominant symptoms in irritable bowel syndrome correlate with specific autonomic nervous system abnormalities. Gastroenterology (1994) 2.44
Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med (1995) 2.26
A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS (1999) 2.23
Rapid and sensitive viral culture method for human immunodeficiency virus type 1. J Clin Microbiol (1988) 2.22
Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA. J Infect Dis (1994) 2.15
Viricidal effect of Lactobacillus acidophilus on human immunodeficiency virus type 1: possible role in heterosexual transmission. J Exp Med (1991) 2.04
Quantitation of human immunodeficiency virus type 1 RNA in plasma by using blood dried on filter paper. J Clin Microbiol (1998) 2.03
Diagnosis of infection with human immunodeficiency virus type 1 by a DNA polymerase chain reaction assay among infants enrolled in the Women and Infants' Transmission Study. J Pediatr (1996) 2.02
Infection of Macaca nemestrina by human immunodeficiency virus type-1. Science (1992) 2.01
Mononuclear leukocytes preferentially bind via CD44 to hyaluronan on human intestinal mucosal smooth muscle cells after virus infection or treatment with poly(I.C). J Biol Chem (1999) 2.01
Comparative stabilities of quantitative human immunodeficiency virus RNA in plasma from samples collected in VACUTAINER CPT, VACUTAINER PPT, and standard VACUTAINER tubes. J Clin Microbiol (1995) 1.98
The selective loss of lysophospholipids in some commonly used lipid-extraction procedures. Anal Biochem (1974) 1.97
Impact of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv network for prevention trials 012 study). J Infect Dis (2001) 1.93
Performance characteristics of serologic tests for human immunodeficiency virus type 1 (HIV-1) antibody among Minnesota blood donors. Public health and clinical implications. Ann Intern Med (1989) 1.84
Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Neurology (2003) 1.83
A longitudinal analysis of the association between menopause and depression. Results from the Massachusetts Women's Health Study. Ann Epidemiol (1994) 1.81
Early detection of human immunodeficiency virus on dried blood spot specimens: sensitivity across serial specimens. Women and Infants Transmission Study Group. J Pediatr (1996) 1.79
Diversity and extinction of tropical american mollusks and emergence of the isthmus of panama. Science (1993) 1.79
Chromatin fractionation procedure that yields nucleosomes containing near-stoichiometric amounts of high mobility group nonhistone chromosomal proteins. Biochemistry (1979) 1.72
Comparison of transcranial color Doppler imaging (TCDI) and transcranial Doppler (TCD) in children with sickle-cell anemia. Pediatr Radiol (2001) 1.65
In vivo studies on pathways for the biosynthesis of lecithin in the rat. J Lipid Res (1966) 1.64
Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. Hepatology (2000) 1.64
Evolutionary significance of morphospecies: a test with cheilostome bryozoa. Science (1990) 1.62
Absolute copy number and relative change in determinations of human immunodeficiency virus type 1 RNA in plasma: effect of an external standard on kit comparisons. J Clin Microbiol (1998) 1.60
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
Determinations of levels of human immunodeficiency virus type 1 RNA in plasma: reassessment of parameters affecting assay outcome. TUBE Meeting Workshop Attendees. Technology Utilization for HIV-1 Blood Evaluation and Standardization in Pediatrics. J Clin Microbiol (1998) 1.58
Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci U S A (1993) 1.58
Recovery of human immunodeficiency virus type 1 from semen: minimal impact of stage of infection and current antiviral chemotherapy. J Infect Dis (1991) 1.57
Effect of menstrual cycle on HIV-1 levels in the peripheral blood and genital tract. WHS 001 Study Team. AIDS (2000) 1.54
Multilaboratory comparison of hepatitis C virus viral load assays. J Clin Microbiol (2006) 1.53
Stroke prevention trial in sickle cell anemia. Control Clin Trials (1998) 1.53
A critical analysis of the use of radiation inactivation to measure the mass of protein. Radiat Res (1995) 1.52
Metabolic aspects of peroxisomal beta-oxidation. Biochim Biophys Acta (1991) 1.50
Performance of the applied biosystems ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for sequence-based analysis of HIV-1 in pediatric plasma samples. J Clin Microbiol (2001) 1.47
Sulfated carbohydrate compounds prevent microbial adherence by sexually transmitted disease pathogens. Antimicrob Agents Chemother (1997) 1.46
Comparison of quantitative and qualitative PCR assays for cytomegalovirus DNA in plasma. J Clin Microbiol (2001) 1.45
A menstrual cycle pattern for cytokine levels exists in HIV-positive women: implication for HIV vaginal and plasma shedding. AIDS (2001) 1.45
Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler. Ann Neurol (1997) 1.44
Transmission of genital herpes in couples with one symptomatic and one asymptomatic partner: a prospective study. J Infect Dis (1988) 1.44
Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr (1995) 1.43
Genetic evaluation of suspected cases of transient HIV-1 infection of infants. Science (1998) 1.43
Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS Res Hum Retroviruses (1995) 1.42
Ion transport induced by light and antibiotics IN CHROMATOPHORES FROM Rhodospirillum rubrum. Eur J Biochem (1968) 1.42
Direct and quantitative detection of HIV-1 RNA in human plasma with a branched DNA signal amplification assay. AIDS (1993) 1.42
Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med (1993) 1.42
Observation of a centrality-dependent dijet asymmetry in lead-lead collisions at sqrt[S(NN)] =2.76 TeV with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.41
Risk factors for HIV infection in homosexual men: the Cleveland men's study of risks in a low-prevalence area. Cleve Clin J Med (1992) 1.41
Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study. AIDS (1998) 1.40
Measurement of dijet azimuthal decorrelations in pp collisions at sqrt(s)=7 TeV. Phys Rev Lett (2011) 1.39
The outer carnitine palmitoyltransferase and regulation of fatty acid metabolism in rat liver in different thyroid states. Biochim Biophys Acta (1983) 1.38
Electron flow to dimethylsulphoxide or trimethylamine-N-oxide generates a membrane potential in Rhodopseudomonas capsulata. Arch Microbiol (1983) 1.35
Determination of the strange-quark density of the proton from ATLAS measurements of the W→ℓν and Z→ℓℓ cross sections. Phys Rev Lett (2012) 1.34
The relative contributions of endocrine changes and social circumstances to depression in mid-aged women. J Health Soc Behav (1987) 1.33
Pyruvate dehydrogenase, substrate specificity and product inhibition. Eur J Biochem (1969) 1.33
Short-chain fatty acid activation in rat liver. A new assay procedure for the enzymes and studies on their intracellular localization. Biochim Biophys Acta (1968) 1.33
Dried-plasma transport using a novel matrix and collection system for human immunodeficiency virus and hepatitis C virus virologic testing. J Clin Microbiol (2009) 1.32
The effect of light on the antibacterial activity of beta-thujaplicin. Can J Microbiol (1973) 1.32
Search for new particles in two-jet final states in 7 TeV proton-proton collisions with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.32
Detection and quantitation of human immunodeficiency virus type 1 in the female genital tract. The Division of AIDS Treatment Research Initiative 009 Study Group. J Clin Microbiol (2000) 1.31
Metabolism of very long-chain monounsaturated fatty acids (22:1) and the adaptation to their presence in the diet. J Lipid Res (1982) 1.30
Factors controlling the rate of fatty acid -oxidation in rat liver mitochondria. Biochim Biophys Acta (1972) 1.30
Multicenter comparison of the digene hybrid capture CMV DNA assay (version 2.0), the pp65 antigenemia assay, and cell culture for detection of cytomegalovirus viremia. J Clin Microbiol (1999) 1.30
Studies with isolated surviving rat hearts. Interdependence of free amino acids and citric-acid-cycle intermediates. Eur J Biochem (1973) 1.29
Observation of associated near-side and away-side long-range correlations in sqrt[s(NN)]=5.02 TeV proton-lead collisions with the ATLAS detector. Phys Rev Lett (2013) 1.27
Intermittent shedding of human immunodeficiency virus in semen: implications for sexual transmission. J Urol (1995) 1.27
Association of antiretroviral therapy with detection of HIV-1 RNA and DNA in the anorectal mucosa of homosexual men. AIDS (2000) 1.27
Recent brachiopod-coralline sponge communities and their paleoecological significance. Science (1971) 1.27
A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob Agents Chemother (2000) 1.27